<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Thorne, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida </em>species are a common cause of fungal endophthalmitis. This infection arises in two distinct ways:</p><p class="bulletIndent1"><span class="glyph">●</span>The endogenous form follows candidemia, with hematogenous seeding of the eye. Fungi usually first seed the highly vascular choroid, then infection typically progresses through the retina into the vitreous. The aqueous is sometimes involved as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The exogenous form follows trauma, eye surgery, or rarely progression of fungal keratitis (corneal infection). Fungi are directly inoculated into the aqueous and/or vitreous. (See  <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">"Treatment of exogenous endophthalmitis due to Candida species"</a>.)</p><p></p><p>The management of endogenous endophthalmitis due to <em>Candida</em> species will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of fungal endophthalmitis are discussed separately. The management of exogenous endophthalmitis due to <em>Candida</em> species and endophthalmitis due to molds are also presented elsewhere. Bacterial endophthalmitis, <em>Fusarium </em>keratitis, and candidemia and other types of <em>Candida</em> infection are also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">"Treatment of exogenous endophthalmitis due to Candida species"</a> and  <a class="medical medical_review" href="/z/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds"</a> and  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">"Treatment and prevention of Fusarium infection", section on 'Keratitis'</a> and  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a>.)</p><p class="headingAnchor" id="H377352637"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The term "ocular candidiasis" refers to both chorioretinitis and endophthalmitis. Although the term "<em>Candida</em> endophthalmitis" is sometimes used to mean both <em>Candida</em> chorioretinitis and endophthalmitis, these infections should be clearly distinguished. Endophthalmitis means infection of the vitreous and/or aqueous, while chorioretinitis means infection of the choroid and retina but without significant vitritis  (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>).</p><p>Eye involvement in candidemia usually presents first as chorioretinitis, then progresses to endophthalmitis if no treatment is given. In many series of inpatients with candidemia in which screening eye examinations are performed, chorioretinitis is approximately 10 times more common than endophthalmitis. (See  <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a>.) </p><p>We will note the distinction between chorioretinitis alone and <em>Candida</em> endophthalmitis (ie, infection that extends to involve the vitreous and/or aqueous) throughout this topic because the approach to treatment differs.</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>No controlled trials of treatment regimens for endogenous <em>Candida </em>chorioretinitis and endophthalmitis have been performed, but prospective trials for treatment of candidemia, along with retrospective series of patients with <em>Candida</em> chorioretinitis or endophthalmitis, have provided insights regarding the choice of therapy for ocular candidiasis (see  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>). In addition to systemic therapy, intravitreal injections of antimicrobial agents have been shown in many studies to be an important component in endophthalmitis, including fungal.</p><p>The approach to treatment must take into account the site and stage of infection, the pharmacology of the available antifungal agents, and existing clinical experience [<a href="#rid1">1,2</a>]. Our recommendations are generally in keeping with the 2016 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis [<a href="#rid3">3</a>]. </p><p>Patients who have chorioretinitis can be treated with a systemic antifungal agent alone unless the lesions threaten the macula or there is vitritis (ie, endophthalmitis). For macula-threatening lesions or endophthalmitis, we recommend an intravitreal injection of an antifungal agent (<a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or amphotericin) along with systemic antifungal therapy  (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>). For patients with endophthalmitis, vitrectomy followed by an intravitreal injection of an antifungal agent is beneficial, in addition to systemic antifungal therapy. </p><p>The prognosis for <em>Candida</em> chorioretinitis and endophthalmitis depends on early diagnosis and appropriate therapy. Close follow-up by an ophthalmologist is required. (See <a class="local">'Outcomes'</a> below.)</p><p class="headingAnchor" id="H149720728"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>Treatment of endogenous <em>Candida</em> endophthalmitis varies depending on whether only chorioretinitis is present, whether the macula is threatened, and the degree of vitritis. Patients with this condition should be evaluated and treated by both an ophthalmologist who has been trained to manage this condition (eg, a retina specialist) and an infectious diseases specialist. The systemic antifungal doses recommended below are intended for patients with normal renal function.</p><p class="headingAnchor" id="H2606842169"><span class="h3">Endogenous Candida chorioretinitis (ie, without vitritis)</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with extramacular chorioretinitis without extension into the vitreous, we recommend the following treatment course:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <em>Candida</em> species that are susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, systemic therapy with oral fluconazole (800 mg [12 mg/kg] loading dose, then 400 to 800 mg [6 to 12 mg/kg] orally daily) OR voriconazole (400 mg [6 mg/kg] intravenously [IV] every 12 hours for two doses, then 200 to 300 mg [3 to 4 mg/kg] IV or orally every 12 hours) can be used. For fluconazole-susceptible isolates, fluconazole is preferred over voriconazole because fluconazole has more consistent serum concentrations, less toxicity, and fewer drug-drug interactions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients infected with a fluconazole-resistant species can be treated with systemic <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, as discussed below:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>C. krusei</em>, which is inherently resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> should be used as nearly all strains are still susceptible. There have been rare reports of voriconazole resistance in patients with <em>C. krusei</em> infections who have received prolonged voriconazole therapy [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>C. glabrata</em> isolates that are <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> resistant, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> should be used only if the isolate is shown to be susceptible. It is important to note that cross-resistance between fluconazole and voriconazole is common among <em>C. glabrata</em> isolates, and patients infected with this species should be followed carefully for their response to treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients who present acutely, the IV formulation of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> is recommended initially prior to switching to oral therapy. Oral therapy at a dose of 200 to 300 mg orally twice daily can be used following an initial response to the IV formulation.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with a subacute presentation who are being managed as outpatients, the <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> loading dose can be given orally (400 mg [6 mg/kg] twice a day for two doses), followed by an oral maintenance dose of 200 to 300 mg (3 to 4 mg/kg) twice daily.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>It is important to measure serum trough concentrations of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> four to seven days after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high concentrations that have been associated with adverse events. Available data suggest a therapeutic range between 2 and 5 mcg/mL. In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For fluconazole- and voriconazole-resistant isolates, <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (3 to 5 mg/kg IV daily) is recommended. <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> (100 mg/kg orally daily in four divided doses) can be added for species that are susceptible to this agent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is likely that patients who have only chorioretinitis will respond to therapy with other agents, such as echinocandins, but there is little clinical experience using this approach. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have <strong>macular involvement</strong> with or without extension into the vitreous, we recommend an intravitreal injection of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) in addition to systemic therapy.</p><p></p><p class="headingAnchor" id="H3566581302"><span class="h3">Endogenous Candida endophthalmitis (ie, with vitritis)</span><span class="headingEndMark"> — </span>In patients with endogenous <em>Candida</em> endophthalmitis, we recommend an intravitreal injection of an antifungal agent in addition to systemic antifungal therapy. Vitrectomy may be beneficial in patients with significant vitreitis in order to debride the vitreous; <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or amphotericin is injected into the vitreous at the end of the surgical procedure. The systemic antifungal agent should be one chosen to penetrate the vitreous as discussed below. The intravitreal injection of antifungal may be repeated.</p><p>We recommend the following treatment course for endophthalmitis:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravitreal injection of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic therapy as listed above (see <a class="local">'Endogenous Candida chorioretinitis (ie, without vitritis)'</a> above) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitrectomy in some cases (eg, marked vitritis, failure to respond to intravitreal injections plus systemic therapy)</p><p></p><p>Intravitreal injection of amphotericin B or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> may need to be repeated, typically 48 hours or more after the initial injection if there is no clinical improvement.</p><p>The management of exogenous endophthalmitis caused by <em>Candida </em>species is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">"Treatment of exogenous endophthalmitis due to Candida species"</a>.)</p><p class="headingAnchor" id="H3113532364"><span class="h2">Duration of systemic therapy</span><span class="headingEndMark"> — </span>The optimal duration of systemic antifungal therapy for ocular candidiasis is unknown but is typically four to six weeks [<a href="#rid3">3</a>]. Treatment should continue until all active eye lesions have resolved as determined by serial dilated ophthalmic examinations. The length of treatment will depend on the rapidity of resolution of active eye lesions. Patients who have endophthalmitis generally require a longer duration of therapy than those who have only chorioretinitis.</p><p class="headingAnchor" id="H278914249"><span class="h2">Systemic antifungal therapy</span><span class="headingEndMark"> — </span>Patients who have only chorioretinitis usually respond to systemic antifungal therapy alone but must be closely followed as some cases progress to endophthalmitis despite appropriate therapy [<a href="#rid6">6,7</a>]. In any patient with endogenous <em>Candida</em> chorioretinitis or endophthalmitis, systemic therapy is essential to treat both the eye as well as any other involved organs. (See  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p>When choosing an antifungal agent, it is important to determine the risk of fluconazole-resistant <em>Candida </em>isolates, such as <em>Candida krusei </em>and most <em>Candida glabrata</em> isolates. Susceptibility testing of the isolate, if available, is often helpful in guiding therapy.</p><p class="headingAnchor" id="H148501885"><span class="h3">Amphotericin B and flucytosine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">Liposomal amphotericin B</a> (3 to 5 mg/kg IV daily) has replaced <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.7 to 1 mg/kg IV daily) in most cases in which the latter agent was used for candidemia, given lower renal toxicity with liposomal amphotericin B. Amphotericin B deoxycholate with <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg orally per day in four divided doses) was previously used as one of the preferred treatments for <em>Candida</em> endophthalmitis [<a href="#rid3">3</a>].</p><p>Two major drawbacks of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> are that it achieves poor levels in the vitreous [<a href="#rid6">6</a>] and that it has significant systemic toxicities, particularly nephrotoxicity. There are limited data on the penetration of the lipid formulations of amphotericin into the eye. One study in rabbits that had inflamed eyes noted higher concentrations in both the aqueous and vitreous with infusions of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> when compared with either amphotericin B deoxycholate or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> [<a href="#rid8">8</a>]. A study that included 4 patients with fungal endophthalmitis receiving 200 to 250 mg per day of IV liposomal amphotericin found that levels in aqueous and vitreous were only 0.09 and 0.17 percent of serum levels, respectively [<a href="#rid9">9</a>]. In contrast, <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> achieves excellent concentrations in the eye. However, it can cause concentration-dependent bone marrow toxicity, which commonly occurs in patients with renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H148501892"><span class="h3">Fluconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> has much less toxicity than amphotericin B and achieves concentrations in the vitreous in humans that are approximately 70 percent of that in the plasma [<a href="#rid10">10,11</a>]. Many reports have shown the benefit of fluconazole for the treatment of <em>Candida </em>endophthalmitis [<a href="#rid11">11-15</a>]. However, failures have also been reported [<a href="#rid16">16</a>]. In animal models of <em>Candida</em> endophthalmitis, amphotericin B was superior to fluconazole in one study [<a href="#rid17">17</a>] but not in another [<a href="#rid18">18</a>]. In many of the case reports, the doses of fluconazole (100 to 200 mg orally daily) were likely too low.</p><p class="headingAnchor" id="H148501899"><span class="h3">Voriconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> is being used with increasing frequency for <em>Candida </em>endophthalmitis [<a href="#rid1">1,19-21</a>]. This agent achieves approximately 40 percent of serum concentrations in the vitreous in noninflamed eyes, is available for intravenous or oral administration, and is active against many species of <em>Candida</em>, including some strains of <em>C. glabrata</em> and almost all strains of <em>C. krusei</em> that are resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid22">22</a>]. Voriconazole has an additional advantage of being active against molds, such as <em>Aspergillus</em> spp, which can also cause endophthalmitis [<a href="#rid23">23-26</a>]. Because cross-resistance occurs between fluconazole and voriconazole for <em>C. glabrata</em> isolates, susceptibility testing is recommended to guide therapy. Increasing resistance to voriconazole among strains of <em>C. glabrata</em> is worrisome and may decrease the usefulness of this agent for treating endophthalmitis due to <em>C. glabrata</em>. (See  <a class="medical medical_review" href="/z/d/html/465.html" rel="external">"Antifungal susceptibility testing", section on 'Indications for testing'</a>.)</p><p>In a treatment trial evaluating the efficacy of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> versus amphotericin B followed by <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for candidemia in 370 patients, a post-hoc analysis of outcomes of the subset of patients who had <em>Candida</em> ocular infections noted a favorable response in 29 of 31 evaluable patients (93.5 percent) [<a href="#rid21">21</a>]. The favorable response rate in the voriconazole group was similar to what was observed among patients treated initially with intravenous amphotericin B for three to seven days, followed by oral fluconazole. However, 13 of 44 patients (30 percent) in the voriconazole group and 6 of 16 patients (38 percent) in the amphotericin/fluconazole group were not evaluable because they died or had no follow-up eye examination. Only 4 of the 31 evaluable patients in the voriconazole group had endophthalmitis, whereas 27 had chorioretinitis, which is typically easier to treat.</p><p>In a review of several published reports that included seven patients who had <em>Candida</em> endophthalmitis treated with <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, visual acuities in the six survivors ranged from 20/20 to 20/100 [<a href="#rid1">1</a>]. It is not possible to firmly state that voriconazole was solely responsible for improved visual outcomes, since several of these patients were given other systemic antifungal agents or had intravitreal injection of voriconazole or amphotericin B.</p><p class="headingAnchor" id="H148501906"><span class="h3">Posaconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> has been used in very few patients with ocular fungal infections. Concentrations in the vitreous appear to be low [<a href="#rid1">1</a>]. Currently, it is not recommended as treatment for <em>Candida</em> endophthalmitis.</p><p class="headingAnchor" id="H2676063563"><span class="h3">Isavuconazole</span><span class="headingEndMark"> — </span>Successful treatment with oral <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> has been reported in a single case of <em>Candida dubliniensis</em> endophthalmitis in a patient who failed <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and was intolerant to amphotericin [<a href="#rid27">27</a>]. Data for ocular concentrations of isavuconazole are limited [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H148501913"><span class="h3">Echinocandins</span><span class="headingEndMark"> — </span>The echinocandins do not achieve adequate concentrations in the vitreous, and their role in treating <em>Candida</em> ocular infections is unclear. It is possible that they could treat chorioretinitis without vitreous extension, but only a few case reports have addressed this, and both failure and success have been noted [<a href="#rid1">1,30,31</a>]. Echinocandins may achieve good levels in the highly vascular choroid, but data are sparse in humans. A study of eight eyes in seven patients who were receiving IV <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> and who were scheduled for vitrectomy (six eyes) or enucleation (two eyes) reported mean micafungin concentrations of 21 mcg/mL in the plasma but, 30 to 90 minutes later, only 0.08 mcg/mL in aqueous samples and 0.10 mcg/mL in vitreous samples [<a href="#rid32">32</a>]. Micafungin concentrations in other ocular structures were measured in one enucleated eye and showed reasonable levels in the choroid (5.8 mcg/mL; 34 percent of the plasma level) but lower levels in the retina (1.20 mcg/mL; 7 percent of the plasma level) and vitreous (0.15 mcg/mL; 0.88 percent of the plasma level). Currently, given their poor penetration into the vitreous, echinocandins <strong>cannot be recommended</strong> as treatment for <em>Candida</em> endophthalmitis, and their role in treating chorioretinitis alone is unclear [<a href="#rid1">1</a>].</p><p>It has been suggested that one might gain a sense of the success of echinocandin therapy for treating <em>Candida</em> endophthalmitis by assessing the response to therapy of the few patients with ocular involvement who were included in the large randomized treatment trials of echinocandins for candidemia and invasive candidiasis. A total of 1028 patients received echinocandins in five randomized controlled treatment trials, and 21 were stated to have endophthalmitis [<a href="#rid33">33-37</a>]. Twelve patients (57 percent) were said to have had resolution of the eye infection. Unfortunately, in none of these trials were specific data reported with regards to the extent of ocular involvement (endophthalmitis versus chorioretinitis) or use of intravitreal injections and/or vitrectomy.</p><p class="headingAnchor" id="H278914238"><span class="h2">Intravitreal antifungal agents and vitrectomy</span><span class="headingEndMark"> — </span>Systemic antifungal therapy in combination with intravitreal antifungal injection is the standard of care for patients with endogenous <em>Candida</em> endophthalmitis [<a href="#rid12">12,15,19</a>]. In addition, vitrectomy should be considered in patients with severe vitritis; the best therapeutic strategy appears to be vitrectomy, intravitreal injection of amphotericin B (5 or 10 mcg in 0.1 mL sterile water), or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) and systemic antifungal therapy [<a href="#rid11">11,12,15</a>]. Early vitrectomy may be important for a favorable outcome [<a href="#rid12">12</a>]. In at least one study of 12 patients with <em>Candida</em> endophthalmitis, good outcomes were reported in the seven patients who underwent early vitrectomy (within one week), but poor visual outcomes were noted in four of five patients in whom vitrectomy was delayed or not performed [<a href="#rid12">12</a>]. The extent of vitreal involvement was not detailed in this report.</p><p>Vitrectomy is a surgical procedure and entails the use of a vitrector, which is an instrument inserted into the vitreous that simultaneously cuts and aspirates much of the gel-like vitreous out of the eye. During this process, another cannula infuses a physiologic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solution into the vitreous cavity  (<a class="graphic graphic_figure graphicRef59512" href="/z/d/graphic/59512.html" rel="external">figure 2</a>). Vitreous samples are sent for stains and culture. (See  <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Diagnosis'</a>.)</p><p>Intravitreal injections may be performed with or without vitrectomy and are given at the end of the procedure when vitrectomy is performed. High doses of intravitreal <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> are toxic to the retina, but an intravitreal injection of 5 or 10 mcg (in 0.1 mL sterile water) appears to be safe and may be repeated (usually several days later) if evidence of intraocular infection persists on serial examinations. Patients have received cumulative intravitreal doses of 30 mcg amphotericin B deoxycholate without apparent retinal toxicity [<a href="#rid38">38</a>]. Increasingly, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> is used for intravitreal injection. The usual dosage of voriconazole for intravitreal injection is 100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, giving a final concentration in the vitreous of about 25 mcg/mL.</p><p>More than one intravitreal injection may be necessary. The second injection is usually given at least 48 hours later.</p><p class="headingAnchor" id="H148501932"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>It is difficult to determine the visual outcomes in patients with endogenous <em>Candida</em> endophthalmitis, as many studies combine the outcomes of patients with chorioretinitis and endophthalmitis [<a href="#rid2">2,39</a>]. In general, patients who have chorioretinitis alone have better outcomes than those with endophthalmitis. It also appears that outcomes have improved compared to those reported several decades ago [<a href="#rid21">21</a>]. (See <a class="local">'Voriconazole'</a> above.)</p><p class="headingAnchor" id="H1111786359"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H377352408"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of infection</strong> – <em>Candida</em> species are a common cause of fungal endophthalmitis. This infection arises in two distinct ways:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exogenous <em>Candida</em> endophthalmitis can occur when the yeast enters the eye via the ocular surface (eg, after penetrating eye trauma, eye surgery, or extension from fungal keratitis).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endogenous <em>Candida</em> endophthalmitis or chorioretinitis follow candidemia with hematogenous seeding of the eye, typically starting with the choroid.</p><p></p><p class="bulletIndent2">Ocular candidiasis is the correct term to include both chorioretinitis and endophthalmitis. Ocular candidiasis can lead to irreversible loss of vision. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment</strong> – Treatment of ocular candidiasis varies depending on whether only chorioretinitis is present, whether the macula is threatened, and whether there is extension into the vitreous (endophthalmitis). Chorioretinitis usually responds to systemic antifungal therapy alone, whereas intravitreal injection of an antifungal agent is necessary for eyes with macula-threatening lesions or endophthalmitis. Eyes with endophthalmitis may also require a vitrectomy if there is marked vitritis or if vitritis has not improved with intravitreal antifungal injections and systemic antifungal therapy. (See <a class="local">'Approach to treatment'</a> above and <a class="local">'Definition'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous Candida chorioretinitis (ie, without vitritis)</strong> – In patients with extramacular chorioretinitis, we recommend systemic antifungal therapy targeted to the susceptibility of the pathogen (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). The antifungal doses recommended below are intended for patients with normal renal function. (See <a class="local">'Endogenous Candida chorioretinitis (ie, without vitritis)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <em>Candida</em> species that are susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, systemic therapy with oral fluconazole (800 mg [12 mg/kg] loading dose, then 400 to 800 mg [6 to 12 mg/kg] orally daily) OR voriconazole (400 mg [6 mg/kg] intravenously [IV] every 12 hours for two doses, then 200 to 300 mg [3 to 4 mg/kg] IV or orally every 12 hours) can be used. For fluconazole-susceptible isolates, fluconazole is preferred over voriconazole.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients infected with a fluconazole-resistant species can be treated with systemic <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>. (See <a class="local">'Endogenous Candida chorioretinitis (ie, without vitritis)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For fluconazole- and voriconazole-resistant isolates, <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (3 to 5 mg/kg IV daily) is recommended; <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg orally daily in four divided doses) can be added for species that are susceptible to this agent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have <strong>macular involvement</strong>, in addition to systemic antifungal therapy, we recommend an intravitreal injection of an antifungal agent to quickly achieve high local concentrations (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>); either <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) may be used. (See <a class="local">'Endogenous Candida chorioretinitis (ie, without vitritis)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous Candida endophthalmitis (ie, with vitritis)</strong> – Patients with endophthalmitis require intravitreal injection of an antifungal agent (<a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or amphotericin) in addition to systemic therapy. A vitrectomy is usually indicated, in addition to intravitreal and systemic antifungal therapy, in cases with marked vitreous inflammation or where the eye fails to improve with intravitreal plus systemic therapy. The antifungal doses recommended below are intended for patients with normal renal function. We use the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend intravitreal injection of an antifungal agent (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>); appropriate antifungal agents for intravitreal injection include <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water). In most cases with severe vitritis or that are failing intravitreal plus systemic therapy, we also recommend vitrectomy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, we recommend a systemic antifungal agent targeted to the susceptibility of the pathogen (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>Candida</em> spp susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, fluconazole (800 mg [12 mg/kg] loading dose, then 400 to 800 mg [6 to 12 mg/kg] orally daily) <strong>or</strong> voriconazole (400 mg [6 mg/kg] IV every 12 hours for two doses, then 200 to 300 mg [3 to 4 mg/kg] IV or orally every 12 hours) can be used. If the organism is susceptible to fluconazole, that agent is preferred. In patients who present acutely, the IV formulation of voriconazole is recommended initially prior to switching to oral therapy. Oral voriconazole can be used following an initial response to the IV formulation. Fluconazole is the preferred agent for fluconazole-susceptible isolates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients infected with a fluconazole-resistant species can be treated with systemic <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, as discussed above.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <em>Candida</em> isolates that are resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (3 to 5 mg/kg IV daily) is recommended. <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> (100 mg/kg orally per day in four divided doses) can be added for species that are susceptible to this agent. (See <a class="local">'Endogenous Candida endophthalmitis (ie, with vitritis)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – The optimal duration of systemic antifungal therapy for <em>Candida</em> endophthalmitis is unknown but is typically four to six weeks. Serial dilated ophthalmic examinations are necessary to help determine the ultimate duration of therapy beyond two weeks. Patients with endophthalmitis (ie, vitreous involvement) generally require a longer duration of therapy than those who have only chorioretinitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous endophthalmitis</strong> – The treatment of exogenous <em>Candida</em> endophthalmitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">"Treatment of exogenous endophthalmitis due to Candida species"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.</a></li><li class="breakAll">Durand ML. Endophthalmitis. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th ed, Bennett JE, Dolin R, Blaser MJ (Eds), 2020.</li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Ricardo E, Grenouillet F, Miranda IM, et al. Mechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Ricardo E, Miranda IM, Faria-Ramos I, et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. Antimicrob Agents Chemother 2014; 58:4604.</a></li><li><a class="nounderline abstract_t">GREEN WR, BENNETT JE, GOOS RD. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol 1965; 73:769.</a></li><li><a class="nounderline abstract_t">Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31:6.</a></li><li><a class="nounderline abstract_t">Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002; 46:3719.</a></li><li><a class="nounderline abstract_t">Ando T, Kawakami H, Mochizuki K, et al. Intraocular penetration of liposomal amphotericin B after intravenous injection in inflamed human eyes. J Infect Chemother 2021; 27:1319.</a></li><li><a class="nounderline abstract_t">Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.</a></li><li><a class="nounderline abstract_t">Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 208:147.</a></li><li><a class="nounderline abstract_t">Martínez-Vázquez C, Fernández-Ulloa J, Bordón J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27:1130.</a></li><li><a class="nounderline abstract_t">del Palacio A, Cuétara MS, Ferro M, et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993; 36:193.</a></li><li><a class="nounderline abstract_t">Luttrull JK, Wan WL, Kubak BM, et al. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995; 119:477.</a></li><li><a class="nounderline abstract_t">Akler ME, Vellend H, McNeely DM, et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20:657.</a></li><li><a class="nounderline abstract_t">Nomura J, Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin Infect Dis 1993; 17:888.</a></li><li><a class="nounderline abstract_t">Filler SG, Crislip MA, Mayer CL, Edwards JE Jr. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 1991; 35:288.</a></li><li><a class="nounderline abstract_t">Louie A, Liu W, Miller DA, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999; 43:2831.</a></li><li><a class="nounderline abstract_t">Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135.</a></li><li><a class="nounderline abstract_t">Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871.</a></li><li><a class="nounderline abstract_t">Oude Lashof AM, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis 2011; 53:262.</a></li><li><a class="nounderline abstract_t">Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122:42.</a></li><li><a class="nounderline abstract_t">Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121:735.</a></li><li><a class="nounderline abstract_t">Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932.</a></li><li><a class="nounderline abstract_t">Garbino J, Ondrusova A, Baglivo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34:701.</a></li><li><a class="nounderline abstract_t">Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.</a></li><li><a class="nounderline abstract_t">Sng ECY, Tan AL, Zhou PY, et al. Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report. Open Forum Infect Dis 2021; 8:ofab516.</a></li><li><a class="nounderline abstract_t">Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 2020; 58:417.</a></li><li><a class="nounderline abstract_t">Schmitt-Hoffmann AH, Kato K, Townsend R, et al. Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Sarria JC, Bradley JC, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40:e46.</a></li><li><a class="nounderline abstract_t">Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41:e27.</a></li><li><a class="nounderline abstract_t">Mochizuki K, Sawada A, Suemori S, et al. Intraocular penetration of intravenous micafungin in inflamed human eyes. Antimicrob Agents Chemother 2013; 57:4027.</a></li><li><a class="nounderline abstract_t">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a class="nounderline abstract_t">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a class="nounderline abstract_t">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a class="nounderline abstract_t">Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48:1676.</a></li><li><a class="nounderline abstract_t">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a class="nounderline abstract_t">Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998; 105:522.</a></li><li><a class="nounderline abstract_t">Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 2003; 82:97.</a></li></ol></div><div id="topicVersionRevision">Topic 2446 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239843" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239843" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932372" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867987" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14302507" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3032091" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435667" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33994091" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intraocular penetration of liposomal amphotericin B after intravenous injection in inflamed human eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11864094" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intravenous penetration of fluconazole during endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8065700" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fluconazole in the management of fungal ocular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827257" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8264716" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709972" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of ocular fungal infections with oral fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756492" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of fluconazole in the treatment of candidal endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8286632" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Failure of therapy with fluconazole for candidal endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024963" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10582868" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15652837" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577634" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Voriconazole in the treatment of fungal eye infections: a review of current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765074" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ocular manifestations of candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718293" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742860" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979655" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374371" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169886" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34909437" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613363" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28971866" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714407" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Candida glabrata endophthalmitis treated successfully with caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007519" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23689706" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraocular penetration of intravenous micafungin in inflamed human eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490683" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of caspofungin and amphotericin B for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17568028" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anidulafungin versus fluconazole for invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806055" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419331" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482982" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9499785" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640186" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
